Octoplus Terug naar discussie overzicht

Present at Rodman&Renshaw

1. [verwijderd] 8 mei 2007 17:05

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   OctoPlus to present at Rodman & Renshaw Annual Global Healthcare Conference
   07.05.2007, Leiden, the Netherlands
   
   OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today that its CFO will present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference in Monaco next week.
   
   Hans Pauli, Chief Financial Officer, will present on Tuesday, 15 May at 10:50 AM CEST.
   
   
2. [verwijderd] 8 mei 2007 19:06

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   FOR IMMEDIATE RELEASE
   BIOLEX THERAPEUTICS ANNOUNCES AGREEMENT
   WITH GENMAB FOR NEW CLASS OF ANTIBODIES
   PITTSBORO, NORTH CAROLINA, May 7, 2007 -- Biolex Therapeutics today announced
   an agreement with Genmab A/S, a leading antibody development company. Under the
   agreement Genmab will evaluate Biolex’s patented LEX SystemSM as a potential
   manufacturing platform for antibodies developed with UniBody™, Genmab’s proprietary
   new antibody technology.
   “We are excited to be working with Genmab as their UniBody technology represents a major
   potential advancement in the antibody space and gives us the opportunity to further leverage
   our unique approach to protein production,” said Jan Turek, President and CEO of Biolex.
   “We are pleased that Genmab, a company with world-class antibody expertise, recognizes the
   potential advantages of the LEX System approach to protein expression and antibody
   optimization.”
   About Biolex Therapeutics
   Biolex Therapeutics is developing and commercializing therapeutic proteins based on the
   LEX SystemSM, its patented expression system that enables the production of hard-to-make
   proteins and the optimization of monoclonal antibodies. The Company is developing a
   proprietary pipeline of products that rely upon known mechanisms of action to provide a
   reduced risk profile while targeting large, proven pharmaceutical markets. Biolex’s lead
   clinical candidate, Locteron™, is being developed as a best-in-class controlled-release
   interferon alfa for the treatment of hepatitis C and is currently in Phase 2 testing. The
   Company’s second product candidate, BLX-155, is a direct-acting thrombolytic, designed to
   break up clots in certain diseases such as acute peripheral arterial disease, deep vein
   thrombosis and catheter occlusion. In addition, the unique capabilities of the LEX System
   have led to collaborations with Centocor, Medarex and other leading pharmaceutical/biotech
   companies. Biolex is a venture capital-backed company located in the Research Triangle
   region of North Carolina, United States. For additional information, please visit Biolex’s web
   site at www.biolex.com.
   ###
   Contacts:
   Media: Michelle Linn, Linnden Communications, 774-696-3803, linnmich@comcast.net.
   Investors: Dale Sander, Chief Financial Officer, 858-663-6993, dsander@biolex.com
3. [verwijderd] 8 mei 2007 19:25

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   FOR IMMEDIATE RELEASE
   BIOLEX THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH
   MERIAL FOR ANIMAL HEALTH VACCINES
   - Collaboration encompasses first vaccines to be produced with LEX SystemSM -
   PITTSBORO, NORTH CAROLINA, May 1, 2007 - Biolex Therapeutics today announced
   a strategic collaboration with Merial Limited, a world-leader in animal health, for the
   development of animal health products using Biolex’s patented LEX SystemSM. The
   collaboration will leverage key advantages of the LEX System to provide Merial with high
   quality vaccine antigens. Merial is a joint venture between Merck & Co., Inc. and sanofiaventis.
   During the initial phase of the collaboration, studies will be conducted to evaluate different
   animal vaccines using recombinant proteins produced in the LEX System. Terms include
   research and development support and development milestones during the initial phase of the
   collaboration. Following the conclusion of the studies, Merial may exercise an option
   regarding a worldwide license covering the use of the LEX System for the field of animal
   health.
   “The field of animal health biologics represents a rapidly growing $3 billion market, and we
   are pleased to form this collaboration with an innovative worldwide leader in this field,” said
   Jan Turek, President and CEO of Biolex. “The LEX System is broadly applicable to all
   proteins, including vaccine antigens, and we look forward to working with Merial to develop
   these important animal health products.”
   “We are exploring and developing new ranges of vaccines which employ both conventional
   and novel technologies with the objective of offering enhanced protection to a wide range of
   animal species,” said Dr. Robert Nordgren, Head of Research, Technology Acquisition, and
   North American Biological Development at Merial. “We are eager to continue exploring the
   LEX System as an enabling platform for the development and production of proteins in
   Merial’s growing portfolio of animal vaccines.”
   About Merial
   Merial is a world-leading, innovation-driven animal health company, providing a
   comprehensive range of products to enhance the health, well-being and performance of a wide
   range of animals. Merial employs approximately 5,000 people and operates in more than 150
   countries worldwide. Its 2006 sales were nearly $2.2 billion. Merial Limited is a joint venture
   between Merck & Co., Inc. and sanofi-aventis. For more information, please see
   www.merial.com.
4. [verwijderd] 8 mei 2007 19:30

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   About Biolex Therapeutics
   Biolex Therapeutics is developing and commercializing therapeutic proteins based on the
   LEX SystemSM, its patented expression system that enables the production of hard-to-make
   proteins and the optimization of monoclonal antibodies. The Company is developing a
   proprietary pipeline of products that rely upon known mechanisms of action to provide a
   reduced risk profile while targeting large, proven pharmaceutical markets. Biolex’s lead
   clinical candidate, Locteron™, is being developed as a best-in-class controlled-release
   interferon alfa for the treatment of hepatitis C. The Company’s second product candidate,
   BLX-155, is a direct-acting thrombolytic, designed to break up clots in certain diseases such
   as acute peripheral arterial disease, deep vein thrombosis and catheter occlusion. In addition,
   the unique capabilities of the LEX System have led to collaborations with Centocor, Medarex
   and other leading pharmaceutical/biotech companies. Biolex is a venture capital-backed
   company located in the Research Triangle region of North Carolina, United States. For
   additional information, please visit Biolex’s web site at www.biolex.com.
5. [verwijderd] 8 mei 2007 19:31

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Gaat ook lekker daar.
   
   gr zenzoe
6. [verwijderd] 9 mei 2007 10:12

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   daar is diegene weer met het restant van de 40000 aandelen die hij weer eens in de laat gooit om de koers te drukken. Wat is hier toch de bedoeling van?
7. [verwijderd] 13 mei 2007 10:31

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Maxygen, Inc. (NasdaqGM:MAXY - News) is a biopharmaceutical company which researches and develops protein drugs. The Company's products now in clinical trials include an interferon-alpha for treating Hepatitis C, and a G-CSF for treating neutropenia.
   
   Weet iemand ieds van dit bedrijf is dit concurrentie ?
8. [verwijderd] 13 mei 2007 10:43

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   www.maxygen.com/products-hep.php
9. [verwijderd] 13 mei 2007 10:53

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   www.google.com/search?q=maxygen+en+oc...
   
   Handig.
10. [verwijderd] 24 mei 2007 23:52

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    www.rodmanandrenshaw.com/Conferences....